There was a lot of initial public offering activity in the US during April, but with returns from newly public companies falling again during the month, only two biopharmaceutical companies – MorphoSys AG and Surface Oncology Inc. – managed to launch IPOs. [Sidebar#SC100667]
The average return for the 16 drug developers that went public through April 30 was 9% at the end of...






